Literature DB >> 9687420

Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.

J E Fitzgibbon1, J F John, J L Delucia, D T Dubin.   

Abstract

A total of 201 Staphylococcus aureus isolates were surveyed for susceptibility to ciprofloxacin and trovafloxacin. Of 66 methicillin-resistant isolates, 89% were ciprofloxacin resistant and 6% were also trovafloxacin resistant. Trovafloxacin-resistant strains had unusual patterns of quinoline resistance mutations in DNA topoisomerase genes, including two mutations in the A subunit (encoded by grlA) of topoisomerase IV.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9687420      PMCID： PMC105881     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.

Authors:  A M Sefton; J P Maskell; A M Rafay; A Whiley; J D Williams
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

Review 2.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

3.  Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus.

Authors:  R Novick
Journal:  Virology       Date:  1967-09       Impact factor: 3.616

4.  Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.

Authors:  M Takahata; M Yonezawa; S Kurose; N Futakuchi; N Matsubara; Y Watanabe; H Narita
Journal:  J Antimicrob Chemother       Date:  1996-09       Impact factor: 5.790

7.  Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.

Authors:  T Deguchi; A Fukuoka; M Yasuda; M Nakano; S Ozeki; E Kanematsu; Y Nishino; S Ishihara; Y Ban; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

8.  Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.

Authors:  H F Bonilla; L T Zarins; S F Bradley; C A Kauffman
Journal:  Diagn Microbiol Infect Dis       Date:  1996-09       Impact factor: 2.803

9.  Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.

Authors:  A Z Chaudhry; C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

10.  Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.

Authors:  E E Margerrison; R Hopewell; L M Fisher
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490
View more
  7 in total

1.  Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.

Authors:  C M Bébéar; O Grau; A Charron; H Renaudin; D Gruson; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.

Authors:  D T Dubin; J E Fitzgibbon; M D Nahvi; J F John
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 3.  Strategic Moves of "Superbugs" Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges.

Authors:  Bikash Baral; M R Mozafari
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-13

4.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Studies on the antimicrobial properties of N-acylated ciprofloxacins.

Authors:  Ryan Cormier; Whittney N Burda; Lacey Harrington; Jordan Edlinger; Karthik M Kodigepalli; John Thomas; Rebecca Kapolka; Glen Roma; Burt E Anderson; Edward Turos; Lindsey N Shaw
Journal:  Bioorg Med Chem Lett       Date:  2012-07-01       Impact factor: 2.823

6.  Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.

Authors:  B Fournier; X Zhao; T Lu; K Drlica; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

7.  Clonal Lineages, Antimicrobial Resistance, and PVL Carriage of Staphylococcus aureus Associated to Skin and Soft-Tissue Infections from Ambulatory Patients in Portugal.

Authors:  Carolina Ferreira; Sofia Santos Costa; Maria Serrano; Ketlyn Oliveira; Graça Trigueiro; Constança Pomba; Isabel Couto
Journal:  Antibiotics (Basel)       Date:  2021-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.